Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Mar 1;28(2):1114-1124.
doi: 10.3390/curroncol28020107.

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma

Hal Hirte  1 , Xiaomei Yao  1   2 , Sarah E Ferguson  3   4 , Taymaa May  3   4 , Laurie Elit  1   5
Affiliations
Practice Guideline

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma

Hal Hirte et al. Curr Oncol. .

Abstract

Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types.

Methods: Consistent with the Program in Evidence-based Program's standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers.

Results: We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible.

Keywords: clinical practice guideline; consolidation therapy; evidence-based; maintenance therapy; ovarian cancer; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

We have read and understood Current Oncology’s policy on disclosing conflict of interest and declare the following interests: H.H. reports personal fees from AstraZeneca, personal fees from Merck, outside the submitted work. Dr. L.E. reports grants and personal fees from Astra Zeneca, outside the submitted work. X.Y., S.E.F., and T.M. have declared no conflicts of interest.

References

    1. González-Martín A., Pothuri B., Vergote I., Christensen R.D., Graybill W., Mirza M.R., McCormick C., Lorusso D., Hoskins P., Freyer G., et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2019;381:2391–2402. doi: 10.1056/NEJMoa1910962. - DOI - PubMed
    1. Canadian Cancer Society’s Steering Committee on Cancer Statistics . Soft Tissue Sarcoma Statistics. Canadian Cancer Society; Toronto, ON, Canada: 2020. [(accessed on 25 June 2020)]. Available online: http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/statistic....
    1. Moore K., Colombo N., Scambia G., Kim B.-G., Oaknin A., Friedlander M., Lisyanskaya A., Floquet A., Leary A., Sonke G.S., et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2018;379:2495–2505. doi: 10.1056/NEJMoa1810858. - DOI - PubMed
    1. National Cancer Institute, Cancer Treatment Biologicol Therapies for Cancer. [(accessed on 8 August 2020)];2019 Available online: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-th....
    1. Hirte H., Yao X., Ferguson S.E., May T., Elit L., The Ovarian Cancer guideline Development Group . Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. Ontario Health (Cancer Care Ontario); Toronto, ON, Canada: 2020. Program in Evidence-Based Care Guideline No.: 4–18. - PubMed

Publication types

LinkOut - more resources